Results 101 to 110 of about 27,659 (185)

Real-time platelet P2Y12 receptor occupancy as a promising pharmacodynamics biomarker for bridging the gap between PK/PD of clopidogrel therapy

Acta Pharmaceutica Sinica B
Clopidogrel effectively inhibits platelet aggregation in response to ADP by irreversibly binding to the platelet P2Y12 receptor through its active metabolite. However, the observed discrepancies between the pharmacokinetics (PK) and pharmacodynamics (PD)
Haipeng Li, Yueming Gu, Yumeng Zhao, Aiyun Xu, Dong Sun, Jingkai Gu   +5 more
doaj   +1 more source

Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE‐ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundGuidelines recommend P2Y12 inhibitor therapy for 1 year after myocardial infarction (MI), yet little guidance is provided on antiplatelet management for patients with recurrent ischemic events during that year.
Alexander C. Fanaroff, Lisa A. Kaltenbach, Eric D. Peterson, Mohammed W. Akhter, Mark B. Effron, Timothy D. Henry, Tracy Y. Wang   +6 more
doaj   +1 more source

P2Y12 inhibitors: pharmacologic mechanism and clinical relevance

, 2013
Platelets play a critical role in the pathogenesis of atherothrombotic processes and inhibition of platelet aggregation by antiplatelet therapy is essential and really important in the acute coronary syndromes or in the setting of percutaneous coronary ...
Parisi R, DE LUCA, GIUSEPPE, Fattori R, GENONI, GIULIA, Lupi A, Rognoni A., SECCO, GIOEL GABRIO, Mirabella F, MARINO, Paolo, Agostoni P   +9 more
core   +3 more sources

ATP Release and Purinergic Signaling Potentiate β‐Adrenergic Effects on Brown Adipocytes

Acta Physiologica, Volume 242, Issue 10, October 2026.
ABSTRACT Aim Brown adipose tissue (BAT) specializes in energy consumption and thermogenesis in response to cold stress. Brown adipocytes (BA) express purinergic receptors, yet little is known about the source of extracellular ATP and the role of purinergic signaling, and the potential interaction with β‐adrenergic signaling.
Marco Tozzi, Emilie B. Berggreen, Rui Zhang, Anders Gudiksen, Wei Li, Mathias B. Matz, Henriette Pilegaard, Jacob B. Hansen, Ivana Novak   +8 more
wiley   +1 more source

Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).

PLoS ONE, 2016
Early stent thrombosis (EST) (≤ 30 days after stent implantation) is a relatively rare but deleterious complication of percutaneous coronary intervention (PCI). Administration of newer P2Y12 inhibitors (prasugrel and ticagrelor) combined with aspirin has
Elad Asher, Arsalan Abu-Much, Ilan Goldenberg, Amit Segev, Avi Sabbag, Israel Mazin, Meital Shlezinger, Shaul Atar, Doron Zahger, Arthur Polak, Roy Beigel, Shlomi Matetzky, Platelets and Thrombosis in Sheba-PLATIS Study Group   +12 more
doaj   +1 more source

The lung is more than an organ of gas exchange: immunocompetency, platelets and implications for drug discovery

British Journal of Pharmacology, Volume 183, Issue 20, Page 5999-6006, October 2026.
Abstract The lungs have for a long time been recognised as having pharmacological significance as a specific organ to modulate the pharmacokinetics of endogenous substances needed to maintain homeostasis. The lungs are therefore the site of action of certain drugs that act on these homeostatic processes, resulting in systemic effects on the ...
Simon C. Pitchford
wiley   +1 more source

Intensified P2Y12 inhibition for high-on treatment platelet reactivity

, 2020
High on treatment platelet reactivity (HPR) during treatment with clopidogrel has been consistently found to be strong risk factor for recurrent ischemic events after percutaneous coronary intervention (PCI).
Kreutz, Rolf P., Hugenberg, Daniel W., Mshelbwala, Fakilahyel S.   +2 more
core   +1 more source

Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9336-9345, October 2026.
ABSTRACT Aims To evaluate whether initiation of amiodarone while receiving sulfonylurea is associated with an increased risk of severe hypoglycemia compared with the initiation of other antiarrhythmic agents (flecainide, sotalol, or propafenone) while receiving sulfonylurea. Materials and Methods We conducted a population‐based cohort study using South
Sungho Bea, Hyesung Lee, Young Min Cho, You‐Jung Choi, Ju‐Young Shin, Katsiaryna Bykov   +5 more
wiley   +1 more source

Next‐Generation Manufacturing: The Evolving Role of Biocatalysis in AstraZeneca

ChemBioChem, Volume 27, Issue 17, 14 September 2026.
Biocatalysis is strengthening AstraZeneca's manufacture of active pharmaceutical ingredients through faster development, robust scale‐up, and lower environmental impact. Case studies illustrate where biocatalysis delivers greatest value, while enabling platforms, teams, and partnerships shape its next phase.
Alba Diaz‐Rodriguez, Martin A. Hayes, Keith R. Mulholland, Fernando Tur, Samantha Staniland   +4 more
wiley   +1 more source

Association of perioperative P2Y12 inhibitor administration with outcomes for tandem occlusion: RESCUE AT-LVO sub-study

Frontiers in Neurology
BackgroundWe aimed to clarify the association between intraoperative P2Y12 inhibitor administration during EVT and clinical outcomes in patients with anterior circulation TO stroke.MethodsAmong consecutive patients with acute ischemic stroke (AIS ...
Takeshi Yoshimoto, Takeshi Yoshimoto, Hiroshi Yamagami, Hiroshi Yamagami, Hiroshi Yamagami, Nobuyuki Sakai, Kazutaka Uchida, Manabu Shirakawa, Mikiya Beppu, Kazunori Toyoda, Yuji Matsumaru, Yuji Matsumaru, Yasushi Matsumoto, Kenichi Todo, Mikito Hayakawa, Mikito Hayakawa, Seigo Shindo, Masafumi Morimoto, Masataka Takeuchi, Hirotoshi Imamura, Hiroyuki Ikeda, Kanta Tanaka, Kanta Tanaka, Hideyuki Ishihara, Hiroto Kakita, Takanori Sano, Takanori Sano, Hayato Araki, Tatsufumi Nomura, Fumihiro Sakakibara, Shinichi Yoshimura, for RESCUE AT-LVO Investigators   +31 more
doaj   +1 more source